Hyperthermic Intraperitoneal Chemotherapy (HIPEC) During Surgery
Received Date: Nov 02, 2024 / Published Date: Nov 30, 2024
Abstract
Hyperthermic Intraperitoneal Chemotherapy (HIPEC) has emerged as an effective therapeutic approach for managing peritoneal carcinomatosis, particularly in patients with colorectal, ovarian, gastric, and mesothelioma cancers. HIPEC is performed during surgery, following cytoreductive surgery (CRS) to remove visible tumors. The procedure involves delivering heated chemotherapy directly into the peritoneal cavity, which enhances the cytotoxic effects of the drugs and allows for better penetration into the cancerous tissues. This article explores the principles, indications, outcomes, and challenges associated with HIPEC during cancer surgery. It also highlights recent advancements in HIPEC technology, including improved drug delivery systems and techniques aimed at maximizing patient benefit. Ultimately, the goal of HIPEC is to increase survival rates while minimizing the risk of recurrence in patients with advanced peritoneal cancers.
Keywords: Hyperthermic Intraperitoneal Chemotherapy (HIPEC); Peritoneal carcinomatosis; Cytoreductive surgery; Heated chemotherapy; Cancer surgery
Citation: Theophile D (2024) Hyperthermic Intraperitoneal Chemotherapy (HIPEC) During Surgery. Cancer Surg, 9: 137. Doi: 10.4172/2573-542X.1000137
Copyright: 漏 2024 Theophile D. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Share This Article
Recommended Journals
黑料网 Journals
Article Tools
Article Usage
- Total views: 83
- [From(publication date): 0-0 - Mar 10, 2025]
- Breakdown by view type
- HTML page views: 57
- PDF downloads: 26
